Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 2/20 | 0.56 |
| ▸ | PPARA | Q07869 | 3/20 | 0.52 |
| ▸ | PTPN1 | P18031 | 8/20 | 0.51 |
| ▸ | CDC25B | P30305 | 7/20 | 0.51 |
| ▸ | PTPN2 | P17706 | 4/20 | 0.51 |
| ▸ | CDC25A | P30304 | 3/20 | 0.51 |
| ▸ | PPARG | P37231 | 2/20 | 0.49 |
| ▸ | CTSS | P25774 | 2/20 | 0.47 |
| ▸ | CTSL | P07711 | 1/20 | 0.47 |
| ▸ | CTSB | P07858 | 1/20 | 0.47 |
| ▸ | CTSK | P43235 | 1/20 | 0.47 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.46 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.46 |
| ▸ | MME | P08473 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL304588 | 1.00 | ACE (0.56) | ACEPPARAPTPN1CDC25BPTPN2 | |
| SCHEMBL3784417 | 0.91 | PPARA (0.52) | ACEPPARAPTPN1CDC25BPTPN2 | |
| SCHEMBL18183914 | 0.90 | PTPN1 (0.49) | ACEPPARAPTPN1CDC25BPTPN2 | |
| SCHEMBL10132030 | 0.90 | PTPN1 (0.49) | ACEPPARAPTPN1CDC25BPTPN2 | |
| SCHEMBL756405 | 0.90 | PTPN1 (0.49) | ACEPPARAPTPN1CDC25BPTPN2 | |
| SCHEMBL305197 | 0.89 | CYP19A1 (0.49) | — | |
| SCHEMBL19701644 | 0.87 | PTPN1 (0.43) | ACEPPARAPTPN1CDC25BPTPN2 | |
| SCHEMBL3789613 | 0.87 | HDAC1 (0.49) | ACEPPARAPTPN1CDC25BPTPN2 | |
| SCHEMBL18681590 | 0.85 | CYP19A1 (0.44) | ACEPTPN1CDC25BPTPN2CDC25A | |
| SCHEMBL29034539 | 0.85 | ACE (0.49) | ACEPPARAPTPN1CDC25BPTPN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3681875-B1 | CYCLIC PEPTIDE ANTIBIOTICS | HOFFMANN LA ROCHE (CH) | 2026-01-14 | — | — | EP | disclosed |
| CN-111148739-B | Cyclic peptide antibiotics | 豪夫迈·罗氏有限公司 | 2025-06-03 | — | — | CN | disclosed |
| US-11279735-B2 | Cyclic peptide antibiotics | GENENTECH, INC. (US) | 2022-03-22 | — | — | US | disclosed |
| US-20200331968-A1 | CYCLIC PEPTIDE ANTIBIOTICS | GENENTECH, INC. (US) | 2020-10-22 | — | — | US | disclosed |
| CN-111148739-A | Cyclopeptide antibiotics | 豪夫迈·罗氏有限公司 | 2020-05-12 | — | — | CN | disclosed |
| US-8669266-B2 | Quinoline-carboxamide derivatives as P2Y12 antagonists | SANOFI (FR) | 2014-03-11 | — | — | US | disclosed |
| EP-2210882-A1 | Synthesis of new protected azahistidine, their processes and their use in synthesises | Commissariat à l'Énergie Atomique et aux Énergies Alternatives (FR) | 2010-07-28 | — | — | EP | disclosed |
| WO-2010081882-A2 | SYNTHESIS OF NEW PROTECTED AZAHISTIDINES, THEIR PROCESSES AND THEIR USE IN SYNTHESISES | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2010-07-22 | — | — | WO | disclosed |
| US-20100135999-A1 | QUINOLINE-CARBOXAMIDE DERIVATIVES AS P2Y12 ANTAGONISTS | SANOFI-AVENTIS (FR) | 2010-06-03 | — | — | US | disclosed |
| EP-2148871-A1 | QUINOLINE-CARBOXAMIDE DERIVATIVES AS P2Y12 ANTAGONISTS | Sanofi-Aventis (FR) | 2010-02-03 | — | — | EP | disclosed |
| WO-2008128647-A1 | QUINOLINE-CARBOXAMIDE DERIVATIVES AS P2Y12 ANTAGONISTS | SANOFI-AVENTIS (FR) | 2008-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200331968-A1 | CYCLIC PEPTIDE ANTIBIOTICS | NPPA, LNPEP, CLPP | ACE 221/4885PPARA 455/4885PTPN1 652/4885 |
| US-20100135999-A1 | QUINOLINE-CARBOXAMIDE DERIVATIVES AS P2Y12 ANTAGONISTS | P2RY12, P2RY1, P2RY2 | ACE 2099/4885PPARA 750/4885PTPN1 1384/4885 |
| US-11279735-B2 | Cyclic peptide antibiotics | NPPA, LNPEP, CLPP | ACE 221/4885PPARA 455/4885PTPN1 652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.